echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > For adult lupus nephritis, Hengrui Pharmaceutical's subsidiary SHR-1314 injection was approved for clinical use

    For adult lupus nephritis, Hengrui Pharmaceutical's subsidiary SHR-1314 injection was approved for clinical use

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 20, Hengrui Medicine issued an announcement stating that its subsidiary Suzhou Shengdia Biomedical Co.
    , Ltd.
    has recently received approval from the State Food and Drug Administration to issue a "Drug Clinical Trial Approval Notice" for SHR-1314 injection.
    Carry out clinical trials for the indications of adult lupus nephritis.

    SHR-1314 injection is a recombinant humanized monoclonal antibody that targets human IL-17A independently developed by the company and is intended to treat autoimmune diseases related to the IL-17 pathway.
    At present, 2 IL-17A antibodies have been approved for marketing worldwide.
    Novartis' secukinumab (trade name Cosentyx) has been approved for listing in many countries and regions including the United States, Europe and Japan since 2015.
    Eli Lilly’s ixekizumab (trade name Taltz) has been approved for listing in the United States, Europe, Japan and other countries and regions since 2016.
    Secukinumab and ixekizumab were approved for marketing in China as the first batch of clinically urgently needed new overseas drugs in April and September 2019, respectively.
    After querying the EvaluatePharma database, the sales of secukinumab in 2020 will be 3.
    995 billion U.
    S.
    dollars, and ixekizumab will be 1.
    789 billion U.
    S.
    dollars.

    According to the announcement, up to now, the accumulated research and development expenses of SHR-1314 related research and development projects have been about 211.
    25 million yuan.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.